Ervebo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recurring ebola outbreaks in africa, high mortality rates of ebola virus disease, success of emergency vaccination campaigns, global health organization involvement, increased funding for epidemic response.

The growth in the forecast period can be attributed to strengthening of global pandemic preparedness, expansion of government vaccine stockpiles, rising international health collaborations, increased focus on zoonotic diseases, faster regulatory approvals for emergency vaccines. Major trends in the forecast period include expansion of ring vaccination strategies, focus on outbreak preparedness vaccines, global stockpiling of critical vaccines, single-dose vaccine development, public health emergency immunization programs.

The rising incidence of viral infections is expected to drive the growth of the ervebo market in the coming years. Viral infections occur when a virus invades and replicates within a host’s cells, causing disease that can range in severity depending on the virus and the host’s immune response. The increase in viral infections is fueled by global travel, which enables rapid cross-border transmission, and climate change, which modifies ecosystems and creates conditions conducive to the emergence of new viruses. Ervebo is used to prevent viral infections by vaccinating at-risk populations during outbreaks, often through ring vaccination strategies to contain the spread of Zaire ebolavirus. For example, in January 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that between 20 September 2022 and 10 January 2023, 4,793 contacts were identified and 11,025 alerts were reported. Of these, 8,088 alerts (73%) were investigated, and 7,382 (67%) were confirmed as suspected Ebola cases caused by Sudan ebolavirus. Thus, the growing incidence of viral infections is fueling the expansion of the ervebo market.

The growing investments in healthcare are also expected to support the future growth of the ervebo market. Healthcare investments involve allocating financial resources to healthcare entities, technologies, services, or innovations. These investments are increasing due to rising demand for chronic disease management among aging populations and funding for advanced technologies, such as telemedicine and artificial intelligence, to improve healthcare delivery. Investments in healthcare play a critical role in the development and success of the Ervebo Ebola vaccine by supporting research, clinical trials, production, and distribution. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, a notable rise compared to the 0.9% growth observed in 2022. Therefore, growing healthcare investments are driving the expansion of the ervebo market.

A major trend in the ervebo market is the pursuit of regulatory approvals to increase its availability and expand its global reach. Regulatory drug approvals are formal processes through which national or international health authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), evaluate and authorize new drugs or vaccines for public use. For instance, in August 2023, Merck & Co. Inc., a US-based pharmaceutical company, received FDA approval for ERVEBO (Ebola Zaire Vaccine, Live), permitting its use in children aged 12 months and older. The vaccine is highly effective - 100% effective when administered more than ten days before exposure to the Ebola virus. As a live recombinant viral vaccine, it elicits an immune response without causing the disease. This approval addresses the urgent need for vaccination in younger populations at risk of Ebola virus disease, particularly in past outbreaks where children represented a significant portion of cases.

Major companies operating in the ervebo market are Merck & Co. Inc.

North America was the largest region in the ervebo market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the ervebo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ervebo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the ervebo market by increasing costs for vaccine raw materials, cold-chain equipment, and cross-border distribution logistics. These impacts are most significant in regions dependent on international vaccine supply, particularly parts of Africa and Europe. Government procurement programs face higher acquisition costs and logistical delays. On the positive side, tariffs are promoting regional vaccine manufacturing hubs and improved local production capacity for emergency immunization needs.

The ervebo market research report is one of a series of new reports that provides ervebo market statistics, including ervebo industry global market size, regional shares, competitors with a ervebo market share, detailed ervebo market segments, market trends and opportunities, and any further data you may need to thrive in the ervebo industry. This ervebo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ervebo is a recombinant, live vaccine designed to protect against Ebola virus disease caused by the Zaire ebolavirus species. It is given as a single-dose injection and has played a key role in controlling outbreaks, especially through ring vaccination strategies in affected areas.

The primary clinical indications of ervebo include general immunization and geographically targeted vaccination. General immunization involves the broad administration of vaccines to protect against prevalent infectious diseases. It is supplied through hospital and retail pharmacies and serves various end users, including adults and elderly populations.

The ervebo market consists of sales of products including pre-filled vaccine syringes, cold chain storage solutions, vaccination kits, and training and education materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.